FDA publishes Lykos Therapeutics’ MDMA response

Last week, the FDA announced that it will release complete response letters “promptly after they are issued to sponsors” and released 89 previously unpublished CRLs issued since 2024. That tranche includes the rejection letter that the FDA issued to Lykos Therapeutics last August for MDMA for PTSD. Get the research insights.